Mesenchymal and Phosphatase of Regenerating Liver-3 Status in Circulating Tumor Cells May Serve as a Crucial Prognostic Marker for Assessing Relapse or Metastasis in Postoperative Patients With Colorectal Cancer.
Mesenchymal and Phosphatase of Regenerating Liver-3 Status in Circulating Tumor Cells May Serve as a Crucial Prognostic Marker for Assessing Relapse or Metastasis in Postoperative Patients With Colorectal Cancer.
复制标题
循环肿瘤细胞中再生肝 3 状态的间充质和磷酸酶可能作为结直肠癌术后患者复发或转移评估的关键预后标志物
DOI：
10.14309/ctg.0000000000000265
复制
发表时间：
2020-12
影响因子：
3.6
通讯作者：
Chu Z
中科院分区：
文献类型：
--
作者：
Su P;Lai W;Liu L;Zeng Y;Xu H;Lan Q;Chu Z;Chu Z
简介：循环肿瘤细胞（CTC）和再生肝磷酸酶-3（PRL-3）被认为是转移性结直肠癌（CRC）的重要预后指标。本研究探讨了间充质CTCs与PRL-3（M+ PRL-3+ CTCs）在结直肠癌术后患者中的预后意义。方法：我们检测了156例患者外周血CTC亚型（包括上皮CTC、双表型上皮/间质CTC和间质CTC）和CTC中的PRL-3。进行受试者工作特征曲线分析、Kaplan-Meier分析和考克斯比例风险回归分析以确定PRL-3+间充质CTC的预后价值。采用免疫组织化学方法检测部分患者肿瘤组织中PRL-3的表达，探讨CTCs与组织之间的联系。结果：所有样本中所有CTCs均为阳性，包括间充质CTCs和PRL-3阳性细胞。间充质细胞和PRL-3+ CTC计数与复发显著相关，最佳临界值为2（曲线下面积= 0.690，P < 0.001）。此外，根据多变量和多项logistic回归，这些患者的中位无病生存期明显短于不符合标准的患者（8.5 vs 24个月，P < 0.001）。应用免疫组化方法探讨PRL-3表达与显著预后危险因素之间的关系，包括复发（R = 0.566; P < 0.001）和CTC中M+ PRL-3+状态（R = 0.452; P = 0.001）。讨论：M+ PRL-3+在CTC中的状态可作为评估CRC临床结局的重要预后标志物。
INTRODUCTION: Circulating tumor cells (CTCs) and phosphatase of regenerating liver-3 (PRL-3) have been considered to be significant prognostic indicators in metastatic colorectal cancer (CRC). This study discusses the prognostic significance of mesenchymal CTCs with PRL-3 (M+ PRL-3+ CTCs) in postoperative patients with CRC. METHODS: We detected CTC subtypes (including epithelial CTCs, biphenotypic epithelial/mesenchymal CTCs, and mesenchymal CTCs) and PRL-3 in CTCs from the peripheral blood samples of 156 patients. Receiver operating characteristic curve analysis, Kaplan-Meier analysis, and Cox proportional hazards regression analysis were performed to identify the prognostic value of mesenchymal CTCs with PRL-3+. Immunohistochemistry was used to detect the expression of PRL-3 in tumor tissues from some of the patients to explore the connection between CTCs and tissues. RESULTS: All CTCs were positive in all samples, both mesenchymal CTCs and PRL-3–positive cells. The count of mesenchymal and PRL-3+ CTCs was significantly associated with recurrence, and the optimal cutoff value was 2 (area under the curve = 0.690, P < 0.001). In addition, these patients had a significantly shorter median disease-free survival than those who did not fulfill the criteria (8.5 vs 24 months, P < 0.001) according to multivariable and multinomial logistic regression. Immunohistochemistry was applied to explore the associations between PRL-3 expression and significant prognostic risk factors, including recurrence (R = 0.566; P < 0.001), and M+ PRL-3+ status in CTCs (R = 0.452; P = 0.001). DISCUSSION: The status of M+ PRL-3+ in CTCs may serve as a crucial prognostic marker for assessing clinical outcomes in CRC.